Search results
Lilly (LLY) Gets FDA Nod for Pediatric Use of Diabetes Drugs
Zacks via Yahoo Finance· 11 months agoFollowing FDA's label expansion approval, Lilly's (LLY) Jardiance and Synjardy are the first SGLT2...
Lilly, Boehringer say Jardiance slows kidney disease progression in trial
Reuters via Yahoo News· 2 years agoBoehringer Ingelheim and Eli Lilly said their diabetes drug Jardiance was shown to slow the...
Lilly-Boehringer Partnered Jardiance Slows Kidney Disease Progression, Data Shows
Benzinga via Yahoo Finance· 2 years agoBoehringer Ingelheim and Eli Lilly And Co (NYSE: LLY) said their diabetes drug Jardiance showed to...
FDA Approves New Class of Oral Medicines for Children with Type 2 Diabetes
Benzinga via Yahoo Finance· 11 months agoOn Tuesday, the FDA approved Jardiance (empagliflozin) and Synjardy (empagliflozin and metformin...
Could This New Drug Indication Be a Winner for Eli Lilly?
Motley Fool· 1 year agoEli Lilly (NYSE: LLY) and Boehringer Ingelheim's supplemental New Drug Application for Jardiance...
Pharma Stock Roundup: JNJ Q4 Results Mixed, MRK Keytruda Prostate Cancer Study Ends
Zacks via Yahoo Finance· 1 year agoThis week, J&J JNJ began the fourth-quarter earnings season for the drug and biotech sector with...
Lilly (LLY) Up 7.5% Since Last Earnings Report: Can It Continue?
Zacks via Yahoo Finance· 3 months agoA month has gone by since the last earnings report for Eli Lilly (LLY). Shares have added about 7.5%...
Eli Lilly and Co (LLY) Q3 2023 Earnings: 37% Revenue Growth and Business Development Activity
GuruFocus.com via Yahoo Finance· 7 months agoRevenue in Q3 2023 increased 37%, driven by growth from Mounjaro, Verzenio, and Jardiance, as well...
Biden targets diabetes drug Jardiance, blood thinner Eliquis, and 8 others for controversial...
Fortune via Yahoo Finance· 9 months agoThe move is expected to cut costs in a few years for some patients but faces litigation from the...
4 Reasons Why 2024 Could Be Eli Lilly's Worst Year for the Rest of This Decade
Motley Fool via Yahoo Finance· 3 months agoEli Lilly (NYSE: LLY) had a very good year in 2023. Revenue jumped 20% and its stock skyrocketed...